HGH Fragment 176-191 vs Tirzepatide

HGH Fragment 176-191: The unmodified C-terminal fragment of growth hormone — the original lipolytic peptide. Typical dose 250-500 mcg. Tirzepatide: Dual GIP/GLP-1 receptor agonist delivering unprecedented weight loss and metabolic benefits. Typical dose 2500-15000 mcg. Both fall under the Weight Management category.

Stacking HGH Fragment 176-191 with Tirzepatide is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

HGH Fragment 176-191 is typically dosed: Once daily, morning, on an empty stomach (SubQ) for Fat loss / body recomposition; Twice daily (morning + pre-cardio), fasted for Split-dose protocol for stubborn fat. Tirzepatide is typically dosed: Once weekly (SubQ) for Type 2 diabetes (Mounjaro); Once weekly (SubQ, titrated over 20 weeks) for Weight management (Zepbound).

HGH Fragment 176-191: Not FDA approved. Distinct from AOD-9604, which holds GRAS status as a food additive. Tirzepatide: FDA approved. Mounjaro (2022) for type 2 diabetes, Zepbound (2023) for chronic weight management, and (2024) for obstructive sleep apnea in adults with obesity.